Hemogenyx Pharmaceuticals PLC Changes to 2021 AGM Arrangements (9728B)
15 June 2021 - 9:41PM
UK Regulatory
TIDMHEMO
RNS Number : 9728B
Hemogenyx Pharmaceuticals PLC
15 June 2021
15 June 2021
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the "Company")
Changes to 2021 AGM Arrangements
Hemogenyx Pharmaceuticals plc (LSE: HEMO) announces that as a
result of the continuation in force of COVID-19 restrictions to 19
July announced by the UK Government, and in order to protect the
health and safety of the Company's Shareholders and Directors, the
Company's Annual General Meeting to be held on 25 June 2021 (the
"AGM") will be held as a closed meeting, as previously allowed for
in the Notice of Annual General Meeting and announcement of 28 May
2021.
The AGM will be attended by two specified Shareholders, being
officers of the Company, to ensure that the meeting is quorate.
These Shareholders will observe all appropriate measures including
social distancing. Other Shareholders and their proxies should not
attend the AGM in person as they will not be allowed to join the
meeting.
Shareholders are strongly encouraged to submit their votes by
proxy in advance and to appoint "the Chair of the AGM" as their
proxy. If a Shareholder appoints someone else as their proxy, that
proxy will not be able to attend the meeting in order to cast the
Shareholder's vote.
The Directors consider the AGM to be an important part of the
Company's shareholder engagement, and to ensure that transparency
is retained arrangements have been made for an electronic facility
which enables shareholders to access the AGM remotely and follow
the business of the AGM by webcast and submit questions relating to
the business of the meeting.
It is important to note that Shareholders following the AGM in
this way will not be formally in attendance at the AGM and will not
be able to vote at the AGM via the electronic facility. In
accordance with article 55.1 of the Company's articles of
association, the Directors have taken the decision that voting on
the resolutions at the AGM will be taken on a poll, rather than a
show of hands, to ensure that Shareholders' proxy votes are
recognised. On a poll, each Shareholder has one vote for each
ordinary share held. All of the votes of the Shareholders present
will be counted, and added to those received by proxy, and the
provisional final votes will be displayed at the AGM and via the
electronic facility. The results of the poll will be announced
shortly after the AGM via the Regulatory News Service and published
on the Company's web site.
Shareholders wishing to raise any questions relating to the
business of the AGM may do so by submitting them to the Chair of
the AGM by email to headquarters@hemogenyx.com in advance of the
AGM. The Company will endeavour to publish and maintain an
appropriate summary of responses on its website in advance of the
AGM. Shareholders will also be permitted to submit written
questions via the electronic facility to the Directors during the
course of the AGM.
Enquiries:
Hemogenyx Pharmaceuticals plc https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive
Officer & Co-Founder headquarters@hemogenyx.com
Peter Redmond, Director peter.redmond@hemogenyx.com
Tel: +44 (0)20 3470
SP Angel Corporate Finance LLP 0470
Matthew Johnson, Vadim Alexandre,
Adam Cowl
Tel: +44 (0)20 7469
Peterhouse Capital Limited 0930
Lucy Williams, Duncan Vasey, Charles
Goodfellow
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE:
HEMO) headquartered in London, with its US operating subsidiaries,
Hemogenyx Pharmaceuticals LLC and Immugenyx LLC, located in New
York City at its state-of-the-art research facility.
The Company is a pre-clinical stage biopharmaceutical group
developing new medicines and treatments to treat blood and
autoimmune disease and to bring the curative power of bone marrow
transplantation to a greater number of patients suffering from
otherwise incurable life-threatening diseases. Hemogenyx
Pharmaceuticals is developing several distinct and complementary
product candidates, as well as platform technologies that it uses
as engines for novel product development.
For more than 50 years, bone marrow transplantation has been
used to save the lives of patients suffering from blood diseases.
The risks of toxicity and death that are associated with bone
marrow transplantation, however, have meant that the procedure is
restricted to use only as a last resort. The Company's technology
has the potential to enable many more patients suffering from
devastating blood diseases such as leukemia and lymphoma, as well
as severe autoimmune diseases such as multiple sclerosis, aplastic
anemia and systemic lupus erythematosus (Lupus), to benefit from
bone marrow transplantation.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDKPBNDBKDCAD
(END) Dow Jones Newswires
June 15, 2021 07:41 ET (11:41 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Apr 2024 to May 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From May 2023 to May 2024